Human Manganese Superoxide Dismutase Target Sequence Polymorphism and Ovarian Cancer

por Bag, A, Bag, N
Publicado 2014

Immunotherapy of melanoma

por Haanen, John B.A.G.
Publicado 2013

Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers

por Tas, Liselotte, Jedema, Inge, Haanen, John B.A.G.
Publicado 2023

A conjunctival myxoid stromal tumor (COMST) mimicking phlyctenulosis: A case report and brief review of the literature

por Medagoda, Kushan, Salvin, K.A., Mahendra, B.A.G. Gayana
Publicado 2022

Selective Expansion of Cross-Reactive Cd8(+) Memory T Cells by Viral Variants

por Haanen, John B.A.G., Wolkers, Monika C., Kruisbeek, Ada M., Schumacher, Ton N.M.
Publicado 1999

Fixed Dosing of Monoclonal Antibodies in Oncology

por Hendrikx, Jeroen J.M.A., Haanen, John B.A.G., Voest, Emile E., Schellens, Jan H.M., Huitema, Alwin D.R., Beijnen, Jos H.
Publicado 2017

Exposure to PCBs and p,p′-DDE and Human Sperm Chromatin Integrity

por Rignell-Hydbom, Anna, Rylander, Lars, Giwercman, Aleksander, Jönsson, B.A.G., Lindh, Christian, Eleuteri, Patrizia, Rescia, Michele, Leter, Giorgio, Cordelli, Eugenia, Spano, Marcello, Hagmar, Lars
Publicado 2005

Spermatocytic tumor of the testis: A case report and mini‑review of the literature

por Bapir, Rawa, Aghaways, Ismaeel, Ali, Rawa M., Fakhralddin, Saman S., Ali, Rebaz M., Rashid, Rezheen J., Abdullah, Ari M., Ali, Muhammed Bag A., Mohammed, Karukh K., Abdullah, Hiwa O., Kakamad, Fahmi H.
Publicado 2023

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characterist...

por van der Hiel, Bernies, Haanen, John B.A.G., Stokkel, Marcel P.M., Peeper, Daniel S., Jimenez, Connie R., Beijnen, Jos H., van de Wiel, Bart A., Boellaard, Ronald, van den Eertwegh, Alfons J.M.
Publicado 2017

T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN-γ, TNF-α or IL-2 production

por van Asten, Saskia D., de Groot, Rosa, van Loenen, Marleen M., Castenmiller, Suzanne M., de Jong, Jeroen, Monkhorst, Kim, Haanen, John B.A.G., Amsen, Derk, Bex, Axel, Spaapen, Robbert M., Wolkers, Monika C.
Publicado 2021

Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment

por Meerveld-Eggink, Aafke, Graafland, Niels, Wilgenhof, Sofie, Van Thienen, Johannes V., Lalezari, Ferry, Grant, Michael, Szabados, Bernadett, Abu-Ghanem, Yasmin, Kuusk, Teele, Boleti, Ekaterini, Blank, Christian U., Haanen, John B.A.G., Powles, Thomas, Bex, Axel
Publicado 2022

Dual Immune Checkpoint Blockade Induces Analogous Alterations in the Dysfunctional CD8(+) T-cell and Activated Treg Compartment

por van der Leun, Anne M., Traets, Joleen J.H., Vos, Joris L., Elbers, Joris B.W., Patiwael, Sanne, Qiao, Xiaohang, Machuca-Ostos, Mercedes, Thommen, Daniela S., Haanen, John B.A.G., Schumacher, Ton N.M., Zuur, Charlotte L.
Publicado 2023

Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evi...

por Fransen van de Putte, Elisabeth E., van den Brink, Luna, Mansour, Mohamed A., van der Mijn, Johannes C., Wilgenhof, Sofie, van Thienen, Johannes V., Haanen, John B.A.G., Boleti, Ekaterini, Powles, Thomas, Zondervan, Patricia J., Graafland, Niels M., Bex, Axel
Publicado 2023

Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase...

por Bilen, Mehmet A., Rini, Brian I., Voss, Martin H., Larkin, James, Haanen, John B.A.G., Albiges, Laurence, Pagliaro, Lance C., Voog, Eric G., Lam, Elaine T., Kislov, Nikolay, McGregor, Bradley A., Lalani, Aly-Khan A., Huang, Bo, di Pietro, Alessandra, Krulewicz, Stan, Robbins, Paul B., Choueiri, Toni K.
Publicado 2022

PD-1(T) TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC

por Hummelink, Karlijn, van der Noort, Vincent, Muller, Mirte, Schouten, Robert D., Lalezari, Ferry, Peters, Dennis, Theelen, Willemijn S.M.E., Koelzer, Viktor H., Mertz, Kirsten D., Zippelius, Alfred, van den Heuvel, Michel M., Broeks, Annegien, Haanen, John B.A.G., Schumacher, Ton N., Meijer, Gerrit A., Smit, Egbert F., Monkhorst, Kim, Thommen, Daniela S.
Publicado 2022

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial

por Mackensen, Andreas, Haanen, John B.A.G., Koenecke, Christian, Alsdorf, Winfried, Wagner-Drouet, Eva, Borchmann, Peter, Heudobler, Daniel, Ferstl, Barbara, Klobuch, Sebastian, Bokemeyer, Carsten, Desuki, Alexander, Lüke, Florian, Kutsch, Nadine, Müller, Fabian, Smit, Eveline, Hillemanns, Peter, Karagiannis, Panagiotis, Wiegert, Erol, He, Ying, Ho, Thang, Kang-Fortner, Qing, Schlitter, Anna Melissa, Schulz-Eying, Catrine, Finlayson, Andrew, Flemmig, Carina, Kühlcke, Klaus, Preußner, Liane, Rengstl, Benjamin, Türeci, Özlem, Şahin, Uğur
Publicado 2023

TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients

por Kvistborg, Pia, Shu, Chengyi Jenny, Heemskerk, Bianca, Fankhauser, Manuel, Thrue, Charlotte Albæk, Toebes, Mireille, van Rooij, Nienke, Linnemann, Carsten, van Buuren, Marit M., Urbanus, Jos H.M., Beltman, Joost B., thor Straten, Per, Li, Yong F., Robbins, Paul F., Besser, Michal J., Schachter, Jacob, Kenter, Gemma G., Dudley, Mark E., Rosenberg, Steven A., Haanen, John B.A.G., Hadrup, Sine Reker, Schumacher, Ton N.M.
Publicado 2012

Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study

por de Joode, Karlijn, Dumoulin, Daphne W., Tol, Jolien, Westgeest, Hans M., Beerepoot, Laurens V., van den Berkmortel, Franchette W.P.J., Mutsaers, Pim G.N.J., van Diemen, Nico G.J., Visser, Otto J., Oomen-de Hoop, Esther, Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., Hendriks, Lizza E.L., Haanen, John B.A.G., de Vries, Elisabeth G.E., Dingemans, Anne-Marie C., van der Veldt, Astrid A.M.
Publicado 2020

OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum

por van der Sluis, Tetje C., Beyrend, Guillaume, van der Gracht, Esmé T.I., Abdelaal, Tamim, Jochems, Simon P., Belderbos, Robert A., Wesselink, Thomas H., van Duikeren, Suzanne, van Haften, Floortje J., Redeker, Anke, Ouboter, Laura F., Beyranvand Nejad, Elham, Camps, Marcel, Franken, Kees L.M.C., Linssen, Margot M., Hohenstein, Peter, de Miranda, Noel F.C.C., Mei, Hailiang, Bins, Adriaan D., Haanen, John B.A.G., Aerts, Joachim G., Ossendorp, Ferry, Arens, Ramon
Publicado 2023

Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?

por Schouwenburg, Maartje G., Suijkerbuijk, Karijn P.M., Koornstra, Rutger H.T., Jochems, Anouk, van Zeijl, Michiel C.T., van den Eertwegh, Alfons J.M., Haanen, John B.A.G., Aarts, Maureen J.B., van Akkooi, Alexander C.J., van den Berkmortel, Franchette W.P.J., de Groot, Jan Willem B., Hospers, Geke A.P., Kapiteijn, Ellen, Kruit, Wim H., Piersma, Djura, van Rijn, Rozemarijn S., ten Tije, Albert J., Vreugdenhil, Gerard, van der Hoeven, Jacobus J.M., Wouters, Michel W.J.M.
Publicado 2019